Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb;53(2):183-189.
doi: 10.1016/j.dld.2020.10.024. Epub 2020 Oct 22.

Management of paediatric IBD after the peak of COVID-19 pandemic in Italy: A position paper on behalf of the SIGENP IBD working group

Affiliations
Review

Management of paediatric IBD after the peak of COVID-19 pandemic in Italy: A position paper on behalf of the SIGENP IBD working group

Serena Arrigo et al. Dig Liver Dis. 2021 Feb.

Abstract

Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2, spreading in Italy during the first months of 2020, abruptly changed the way of practicing medicine in this country. As a consequence of the lockdown, the diagnostic and therapeutic management of paediatric chronic conditions, such as inflammatory bowel disease (IBD) has been affected. During the peak of COVID-19 pandemic, elective visits, endoscopies and infusions have been postponed, with potential clinical and psychological impact on disease course and a high likelihood of increasing waiting lists. While slowly moving back towards normality, clinicians need to recognize the best ways to care for patients with IBD, carefully avoiding risk factors for new potential epidemic outbreaks. In this uncertain scenario until the development and spread of COVID-19 vaccine, it is necessary to continue to operate with caution. Hereby we provide useful indications for a safer and gradual restarting of routine clinical activities after COVID-19 peak in Italy.

Keywords: COVID-19; Inflammatory bowel disease; Paediatrics; SARS-CoV2.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors have no conflict of interest to declare.

Similar articles

Cited by

References

    1. Rosenbaum L. Facing Covid-19 in Italy - ethics, logistics, and therapeutics on the epidemic's front line. N Engl J Med. 2020;382:1873–1875. - PubMed
    1. Occhipinti V., Pastorelli L. Challenges in the care of IBD patients during the CoViD-19 pandemic: report from a “red zone” area in northern Italy. Inflamm Bowel Dis. 2020;26:793–796. - PMC - PubMed
    1. Danese S., Cecconi M., Spinelli A. Management of IBD during the COVID-19 outbreak: resetting clinical priorities. Nat Rev Gastroenterol Hepatol. 2020;17:253–255. - PMC - PubMed
    1. Fiorino G., Allocca M., Furfaro F. Inflammatory bowel disease care in the COVID-19 pandemic era: the humanitas, Milan, experience. J Crohns Colitis. 2020;14:1330–1333. - PMC - PubMed
    1. Scaldaferri F., Pugliese D., Privitera G. Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: reorganisational response in a high-volume Italian inflammatory bowel disease centre. United European Gastroenterol J. 2020;8:775–781. - PMC - PubMed